Conquer Cancer Fdn of the American Society of Clinical Oncology
Public records show a registered, tax-exempt organization in good standing.
What it says it does
CONQUER CANCER FUNDS RESEARCH FOR EVERY TYPE OF CANCER TO BENEFIT EVERY PATIENT, EVERYWHERE. WORKING IN COLLABORATION WITH A GLOBAL NETWORK OF TOP SCIENTISTS AND CLINICIANS, AND LEADING ADVOCACY AND RESEARCH ORGANIZATIONS, CONQUER CANCER DRAWS (CONTINUED IN SCHEDULE O) ON THE PASSION AND EXPERTISE OF THE CANCER PROFESSIONALS WHO ARE MEMBERS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO). CONQUER CANCER WORKS TO HELP CREATE A WORLD WHERE CANCER IS PREVENTED OR CURED AND EVERY SURVIVOR IS HEALTHY.
- Income
- $41.4 million
- Spending
- $34.8 million
- Spent on programs
- 67%
- Reserves
- 13.6 months of spending
- Largest source of income
- donations and private grants, 90%
- Employees
- 0
- Volunteers
- 300
- Highest pay
- $1.1 million, executive vice chair
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Financial health
Strong: 100 out of 100. Higher than 91% of charities in its peer group (medical research, $10m to $100m).
Reserves
35 of 35Spendable reserves would cover 13.6 months of spending.
Debt
20 of 20It owes 10% of what it owns.
Living within its means
15 of 15Income exceeded spending by 16% of income.
Income trend
15 of 15Income rose 6% on the year before.
Spending floor
15 of 1567% of spending went to programs and raising each dollar of donations cost 27 cents.
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Governance
Strong: 95 out of 100. Higher than 37% of charities in its peer group (medical research, $10m to $100m).
Independent board
25 of 2520 of 21 voting board members are independent.
Conflict of interest policy
15 of 15Has a written conflict of interest policy.
Whistleblower policy
8 of 8Has a written whistleblower policy.
Record keeping policy
7 of 7Has a written policy on keeping and destroying records.
Board minutes
5 of 5Keeps minutes of board meetings.
Board sees the tax return
10 of 10Gave the board a copy of this return before filing it.
Pay set independently
0 of 5Reports no independent review process for its chief executive's pay.
Independent check of accounts
15 of 15Its accounts were audited by an independent accountant.
No reported misuse
10 of 10Reports no diversion of assets, excess benefits or loans to insiders.
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Impact evidence
Describes programs. Its tax return describes what it does but we have found no measurable results in it.
Programs described in its return (3)
- $15.9 million spent. SEE SCHEDULE O:RESEARCH: RESEARCH IS HOW WE CONQUER CANCER. IT MEANS EVERYTHING, FROM UNDERSTANDING HOW CANCER IMPACTS CERTAIN PEOPLE TO FINDING GROUNDBREAKING NEW WAYS TO TREAT CANCER. THE CONQUER CANCER GRANTS & AWARDS PROGRAM HAS BEEN RECOGNIZING EXCELLENCE IN CLINICAL RESEARCH, QUALITY CARE, AND TEACHING IN THE FIELD OF ONCOLOGY SINCE 1984, WHEN THE PROGRAM ORIGINALLY BEGAN UNDER THE PURVIEW OF ASCO. CONQUER CANCER FUNDS THE ENTIRE SPECTRUM OF RESEARCH ACTIVITIES RELATED TO CANCER PREVENTION, SCREENING, TREATMENT, AND OUTCOMES RESEARCH IN ALL CANCER TYPES, AND SUPPORTS PROGRESS BY FUNDING CANCER RESEARCHERS AT ALL STAGES OF THEIR CAREERS, ENABLING ONCOLOGY'S BEST AND BRIGHTEST TO PURSUE PROMISING RESEARCH. CONQUER CANCER AND ASCO HAVE FUNDED MORE THAN $191 MILLION TO SUPPORT GRANTS & AWARDS TO OVER 9,300 RECIPIENTS IN 90 COUNTRIES. HIGHLIGHTS OF 2024 RESEARCH ACTIVITIES AND ACCOMPLISHMENTS INCLUDE: *ADVANCED CLINICAL RESEARCH AWARD (ACRA): $1,350,000 PROVIDED THREE (3) THREE-YEAR AWARDS TO PHYSICIAN-SCIENTISTS COMMITTED TO SUPPORT CLINICAL CANCER RESEARCH WITH A PATIENT-ORIENTED FOCUS. AWARDS SUPPORTED FOCUSED ON BREAST CANCER RESEARCH. *CAREER DEVELOPMENT AWARD (CDA): $4,200,000 PROVIDED TWENTY-ONE (21) THREE-YEAR AWARDS INTENDED TO SUPPORT CLINICAL RESEARCH OF CLINICAL INVESTIGATORS WHO HAVE RECEIVED THEIR INITIAL FACULTY APPOINTMENTS AND ARE ESTABLISHING INDEPENDENT CLINICAL CANCER RESEARCH PROGRAMS. *YOUNG INVESTIGATOR AWARD (YIA): $4,560,000 PROVIDED NINETY-ONE (91) ONE-YEAR AWARDS DESIGNED TO ENCOURAGE AND PROMOTE HIGH-QUALITY RESEARCH IN CLINICAL ONCOLOGY BY SUPPORTING THE RESEARCH OF PROMISING INVESTIGATORS DURING THE TRANSITION FROM A FELLOWSHIP PROGRAM TO A FACULTY APPOINTMENT. *GLOBAL ONCOLOGY YOUNG INVESTIGATOR AWARD: $300,000 PROVIDED FIVE (6) ONE-YEAR AWARDS TO EARLY-CAREER INVESTIGATORS TO SUPPORT RESEARCH IN GLOBAL ONCOLOGY AND TO DEVELOP THE NEXT GENERATION OF RESEARCHERS TO ADDRESS GLOBAL HEALTH NEEDS. THIS IS A MENTORED AWARD AND THE RESEARCH PROJECT IS CONDUCTED UNDER THE GUIDANCE OF A SCIENTIFIC MENTOR. *INTERNATIONAL INNOVATION GRANT: $39,500 PROVIDED TWO (2) ONE-YEAR AWARDS IN SUPPORT OF NOVEL AND INNOVATIVE PROJECTS THAT HAVE THE POTENTIAL TO REDUCE THE CANCER BURDEN IN LOCAL COMMUNITIES, WHILE ALSO BEING POTENTIALLY TRANSFERRABLE TO OTHER LOW- OR MIDDLE- INCOME SETTINGS. *LONG-TERM INTERNATIONAL FELLOWSHIP: $115,000 PROVIDED ONE (1) ONE YEAR GRANT WHICHENABLES AN EARLY CAREER MEMBER ONCOLOGIST IN A LOW TO MIDDLE INCOME COUNTRY AND THEIR MENTOR IN THE UNITED STATES OR CANADA TO EXTEND THE COLLABORATION THROUGH A RESEARCH FELLOWSHIP AT THE MENTOR'S INSTITUTION.THROUGH ITS EVERYGRANT PROGRAM, CONQUER CANCER UTILIZES ITS SKILLS AND EXPERTISE IN GRANTS ADMINISTRATION AND PROGRAM MANAGEMENT TO COLLABORATE WITH OTHER ORGANIZATIONS TO DEVELOP AND DELIVER PROGRAMS THAT MAKE A DIFFERENCE TO CANCER CARE TEAMS AND PATIENTS EVERYWHERE.
- $6.1 million spent. SEE SCHEDULE O:PROFESSIONAL EDUCATION: CONQUER CANCER SUPPORTS THE EFFORTS OF ASCO TO PROVIDE EDUCATION PROGRAMS IN THE US AND INTERNATIONALLY WHICH PROMOTE THE VITAL EXCHANGE OF IDEAS AND LATEST DEVELOPMENTS THAT LEAD TO WORLD-CLASS CARE, EVERYWHERE. FUNDS FROM CONQUER CANCER ARE USED TO SUPPORT ASCO'S SCIENTIFIC AND EDUCATIONAL PROGRAMS THROUGH BOTH MEETINGS AND ELECTRONIC EDUCATION OFFERINGS. HIGHLIGHTS OF THE PROFESSIONAL EDUCATIONAL AND SCIENTIFIC PROGRAMS SUPPORTED BY CONQUER CANCER AND PRESENTED TO THE PUBLIC IN 2024 INCLUDE THE FOLLOWING: * ASCO ANNUAL MEETING: THE ASCO ANNUAL MEETING IS A GLOBAL GATHERING OF MORE THAN 44,000 PARTICIPANTS WHERE ONCOLOGY PROFESSIONALS CONNECT, COLLABORATE, AND INSPIRE. THE MEETING IS KNOWN FOR ADVANCING THE ONCOLOGY FIELD AND OFFERS AN EXPERIENCE UNLIKE ANY OTHER, BRINGING TOGETHER THE BEST MINDS TO SHAPE THE FUTURE OF CANCER CARE. *GASTROINTESTINAL CANCERS (GI) SYMPOSIUM: THIS IS ONE OF THE PREMIER MULTIDISCIPLINARY GI CANCER SCIENTIFIC AND EDUCATIONAL MEETINGS. THE SYMPOSIUM OFFERS THE LATEST INNOVATIVE SCIENCE, SOLUTION-FOCUSED STRATEGIES, AND MULTIDISCIPLINARY APPROACHES IN GI CANCER TREATMENT, RESEARCH, AND CARE. *GENITOURINARY CANCERS (GU) SYMPOSIUM: THE GU SYMPOSIUM OFFERS AN UNPARALLELED MEETING EXPERIENCE THAT HELPS ATTENDEES TO REMAIN AT THE FOREFRONT OF ADVANCES IN GU CANCER CARE. AS ONE OF THE ONLY WORLD-CLASS SYMPOSIA OF ITS KIND, THE SYMPOSIUM UNVEILS PARADIGM-SHIFTING DISCOVERIES AND FOSTERS COLLABORATIONS THAT WILL TRANSFORM GU CANCER CARE.
- $1.3 million spent. SEE SCHEDULE O:*QUALITY CARE SYMPOSIUM: THIS PREMIER MEETING FOCUSES ON IMPROVING THE QUALITY, SAFETY, AND EFFICIENCY OF CANCER CARE DELIVERY, BRINGING TOGETHER THE ENTIRE CLINICAL CARE TEAM TO EXPLORE THE LATEST ADVANCEMENTS IN QUALITY IMPROVEMENT THROUGH RESEARCH, EDUCATION, AND DISCUSSIONS. *MERIT AND ABSTRACT AWARDS: $294,000 PROVIDED TWO HUNDRED EIGHTY-NINE (289) MERIT AWARDS TO PROMOTE CLINICAL RESEARCH BY AWARDING YOUNG SCIENTISTS WHOSE RESEARCH IS ADDRESSED IN HIGH QUALITY ABSTRACTS SUBMITTED TO ASCO MEETINGS WITH AN OPPORTUNITY TO PRESENT THEIR RESEARCH AT ASCO SCIENTIFIC MEETINGS AND DISEASE SPECIFIC SYMPOSIA. $40,000 PROVIDED FORTY (40) ABSTRACT AWARDS TO THE PRESENTING AUTHORS OF THE 40 HIGHEST-RATED ABSTRACTS SELECTED FOR PRESENTATION AT THE ASCO BREAKTHROUGH MEETING THAT FOCUSES ON HOW INNOVATIONS IN TECHNOLOGY CREATE BOTH SOLUTIONS AND CHALLENGES IN PATIENT CARE AND RESEARCH.
Source: Form 990 for the year ending December 31, 2024, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Legitimacy checks
Is it registered with the IRS? Passed.
Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated September 7, 2026.
Has the IRS revoked its tax-exempt status? Passed.
Not on the IRS automatic revocation list.
Source: Automatic revocation of exemption list, Internal Revenue Service, file dated September 30, 2026.
Are donations tax-deductible? Passed.
On the IRS list of organizations eligible to receive tax-deductible contributions.
Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated September 10, 2026.
Is it keeping up with its IRS filings? Passed.
Most recent return on file covers the year ending December 2024.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated September 7, 2026.
How long has it been tax-exempt? Passed.
Recognized by the IRS since October 1999.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated September 7, 2026.
Is it in good standing with state regulators? Passed.
Not on California's list of charities barred from soliciting. Other states are not yet checked.
Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated October 7, 2026.
Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.